Literature DB >> 25260809

Factor V Leiden 1691G/A and prothrombin gene 20210G/A polymorphisms as prothrombotic markers in adult Egyptian acute leukemia patients.

Azza Hamdy El Sissy1, Maha H El Sissy, Shereef Elmoamly.   

Abstract

Factor V Leiden 1691G/A and prothrombin gene 20210G/A mutations are the most common genetic defects leading to thrombosis. This work aimed to study the FV Leiden and the prothrombin gene polymorphism in adult Egyptian patients with acute leukemia and their importance in thrombophilia screening. The study included 76 patients with acute leukemia and 100 healthy controls. Genotyping was done by real-time polymerase chain reaction technique. For factor V Leiden, the frequency of G/A mutation conferred more than 2.5-fold of increased risk of (OR 2.639 95 % CI 1.045-6.669). The frequency of factor V Leiden combined (G/A + A/A) genotypes conferred 2.83-fold of increased risk (OR 2.828, CI 1.13-7.075), The A allele conferred almost threefold increased risk (OR 2.824, 95 % CI 1.175-6.785). Despite higher frequency in patients compared to controls, there was no risk of association between prothrombin gene mutation and acute leukemia in adult Egyptians nor was there between combined genotypes of prothrombin gene mutation and factor V Leiden.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25260809     DOI: 10.1007/s12032-014-0265-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

1.  Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes).

Authors:  Jacques B de Kok; Erwin T G Wiegerinck; Belinda A J Giesendorf; Dorine W Swinkels
Journal:  Hum Mutat       Date:  2002-05       Impact factor: 4.878

2.  The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.

Authors:  N Irani-Hakime; H Tamim; R Kreidy; W Y Almawi
Journal:  Am J Hematol       Date:  2000-09       Impact factor: 10.047

3.  Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.

Authors:  C Wermes; M von Depka Prondzinski; R Lichtinghagen; M Barthels; K Welte; K W Sykora
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

4.  Factor V 1691 G-A mutation distribution in a healthy Turkish population.

Authors:  Namık Özbek
Journal:  Turk J Haematol       Date:  2009-03-05       Impact factor: 1.831

5.  Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.

Authors:  Dan Harlev; Irina Zaidman; Galit Sarig; Myriam Weyl Ben Arush; Benjamin Brenner; Ronit Elhasid
Journal:  Thromb Res       Date:  2010-05-23       Impact factor: 3.944

6.  The factor V Leiden mutation in children with cancer and thrombosis.

Authors:  M T Sifontes; R Nuss; S P Hunger; J Wilimas; L J Jacobson; M J Manco-Johnson
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

7.  Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.

Authors:  Hamed M Shatla; Hoda Y Tomoum; Solaf M Elsayed; Rasha H Aly; Rania H Shatla; Mona A Ismail; Naglaa A El-Ghany; Arsanios I Fakhry; Nasser A Abd Allah; Egin Yonca; Akar M Nejat
Journal:  Pediatr Neurol       Date:  2012-08       Impact factor: 3.372

8.  Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.

Authors:  N Haim; N Lanir; R Hoffman; A Haim; M Tsalik; B Brenner
Journal:  Am J Med       Date:  2001-02-01       Impact factor: 4.965

9.  A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.

Authors:  Lesley G Mitchell; Maureen Andrew; Kim Hanna; Thomas Abshire; Jacqueline Halton; Ron Anderson; Irene Cherrick; Sunil Desai; Donald Mahoney; Patricia McCuster; John Wu; Gary Dahl; Peter Chait; Gabrielle de Veber; Kyong-Jin Lee; David Mikulis; Jeffrey Ginsberg; Cliford Way
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

10.  Risk of prostate cancer and thrombosis-related factor polymorphisms.

Authors:  Somayehsadat Ghasemi; Aydin Tavakoli; Mohamad Moghadam; Mohamad Ali Zargar; Maryam Abbaspour; Nasim Hatamnejadian; Ahmad Ebrahimi
Journal:  Biomed Rep       Date:  2013-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.